Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 40.0% in February

Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,500 shares, a decrease of 40.0% from the February 13th total of 2,500 shares. Based on an average trading volume of 10,400 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company's stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC bought a new stake in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 11,167 shares of the company's stock, valued at approximately $46,000. Citadel Advisors LLC owned about 0.06% of Genenta Science as of its most recent SEC filing. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Genenta Science Stock Performance

Shares of NASDAQ GNTA traded up $0.05 during mid-day trading on Wednesday, reaching $3.85. 870,814 shares of the company traded hands, compared to its average volume of 15,035. The company's fifty day moving average is $4.03 and its two-hundred day moving average is $4.54. Genenta Science has a fifty-two week low of $2.20 and a fifty-two week high of $7.28.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.